Skip to main content
placeholder image

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study

Journal Article


Abstract


  • Introduction Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. Methods and analysis The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine (��naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing substudies will examine implementation barriers and facilitators at the client and provider level. Ethics and dissemination The study has received ethics approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national and international scientific conferences, and in relevant community organisation publications and forums. Trial registration number NCT03809143 Protocol identifier CoLAB1801, V.4.0 dated 01 August 2019

Publication Date


  • 2020

Publisher


Citation


  • Larance, B., Byrne, M., Lintzeris, N., Nielsen, S., Grebely, J., Degenhardt, L., . . . Farrell, M. (2020). Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study. BMJ Open, 10(7). doi:10.1136/bmjopen-2019-034389

Scopus Eid


  • 2-s2.0-85089126645

Web Of Science Accession Number


Volume


  • 10

Issue


  • 7

Place Of Publication


Abstract


  • Introduction Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. Methods and analysis The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine (��naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing substudies will examine implementation barriers and facilitators at the client and provider level. Ethics and dissemination The study has received ethics approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national and international scientific conferences, and in relevant community organisation publications and forums. Trial registration number NCT03809143 Protocol identifier CoLAB1801, V.4.0 dated 01 August 2019

Publication Date


  • 2020

Publisher


Citation


  • Larance, B., Byrne, M., Lintzeris, N., Nielsen, S., Grebely, J., Degenhardt, L., . . . Farrell, M. (2020). Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study. BMJ Open, 10(7). doi:10.1136/bmjopen-2019-034389

Scopus Eid


  • 2-s2.0-85089126645

Web Of Science Accession Number


Volume


  • 10

Issue


  • 7

Place Of Publication